Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Hypertension US FDA label
Kidney dosing: Amlodipine (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing: 5 mg once daily, maximum 10 mg (label).
- eGFR 30–59
- No adjustment (label).
- eGFR 15–29
- No adjustment (label).
- eGFR <15 (not on dialysis)
- Usual initial dose (label: patients with renal failure).
- Hemodialysis (intermittent)
- No adjustment; hemodialysis is unlikely to remove amlodipine (label, Overdosage).
- Peritoneal dialysis
- No label adjustment; no PD data (amlodipine is hepatically cleared and not dialyzed).
- CRRT
- No data in label.
- Dialyzable? No: highly protein bound; hemodialysis not likely to help (label).
- Monitoring Blood pressure, edema. Lower starting dose (2.5 mg) in older adults and hepatic impairment (label).
From the Amlodipine monograph (renalcarematters.com, reviewed).
- chlorthalidone no separate page
Use: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. US FDA label
Kidney dosing: Losartan (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing: 50 mg once daily, up to 100 mg once daily.
- eGFR 30–59
- No adjustment unless volume depleted (label). Exposure is 50 to 90% higher in mild to moderate impairment.
- eGFR 15–29
- No adjustment unless volume depleted (label). Monitor potassium and creatinine.
- eGFR <15 (not on dialysis)
- No label adjustment; monitor potassium, creatinine and blood pressure closely.
- Hemodialysis (intermittent)
- No adjustment in the label; not removed by hemodialysis.
- Peritoneal dialysis
- No label adjustment; no PD data.
- CRRT
- No data in label.
- Dialyzable? No: neither losartan nor its active metabolite is removed by hemodialysis (label).
- Monitoring Serum creatinine and potassium 2 to 4 weeks after starting or changing the dose; a creatinine rise up to 30% is expected and is not a reason to stop. Correct volume depletion before starting (label). KDIGO 2024 supports continuing the ARB when eGFR falls below 30.
From the Losartan monograph (renalcarematters.com, reviewed).
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 5 mg/100 mg/12.5 mg, 5 mg/100 mg/25 mg, 5 mg/50 mg/12.5 mg
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Chlorthalidone + Losartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Amosartan PlusAmlodipine camsylate + Losartan potassium + Chlorthalidone | 5 mg/100 mg/12.5 mg Film-Coated TabletAlu-Alu blister pack x 10 (Box of 30’s) | Rx | Hanmi Pharm. Co., LimitedSouth Korea | JLT Pharma Inc. | DR-XY49783 | Aug 11, 2031 | |
Amosartan PlusAmlodipine camsylate + Losartan potassium + Chlorthalidone | 5 mg/100 mg/25 mg Film-Coated TabletAlu-Alu blister pack x 10 (Box of 30’s) | Rx | Hanmi Pharm. Co., LimitedSouth Korea | JLT Pharma Inc. | DR-XY49782 | Aug 11, 2031 | |
Amosartan PlusAmlodipine camsylate + Losartan potassium + Chlorthalidone | 5 mg/50 mg/12.5 mg Film-Coated TabletAlu-Alu blister pack x 10 (Box of 30’s) | Rx | Hanmi Pharm. Co., LimitedSouth Korea | JLT Pharma Inc. | DR-XY49784 | Aug 11, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .



